The alternate payment version is just a non traditional financial arrangement which rewards medical care providers that deliver cheap, supreme quality maintenance. Today we're confronting the risk that pharmaceutical makers and carriers will probably adopt APMs like a payment system in a few instances.
As pharmaceutical manufacturers face rising public anxiety over value and prices, we believe the benefits of pharmaceutical alternative payment models is likely to soon be attractive for both pharmaceutical manufacturers and carriers. But pharmaceutical companies APMs are somewhat more aggressive and resource intensive compared to the classic feeforservice contracts which pharmaceutical manufacturers negotiate with creditors. There are a few invaluable lessons for pharmaceutical manufacturers in provider APMs, however, if pharmaceutical APMs fail or succeed will depend upon finding methods to logistical and operational challenges–a number which can be particular to the pharmaceutical trade.
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.